What kind of expertise do you need?


News & Insights
Precision Thought Leadership on Display at ISPOR Barcelona
Precision Thought Leadership on Display at ISPOR Barcelona
Precision's thought leaders will be active throughout ISPOR, presenting their latest research in a variety of short courses, posters, issue panels and workshops. A complete list of scientific presentations can be found below:
Short Course
NETWORK META-ANALYSIS IN RELATIVE EFFECTIVENESS RESEARCH
Led by Precision Xtract's Jeroen P. Jansen and Steve Kanters
Posters
PHP301: THE TIME IS NOW FOR EUROPEAN HTA: HOW WILL THE EVOLUTION OF EUROPEAN HTA IMPACT ACCESS TO INNOVATIVE MEDICINES?
Authors: Laisné E, Allen N, Kolotourou K, Sattler-Ermacora P, Grosvenor A
PHP355: THE FUTURE OF VALUE-BASED CONTRACTING FOR HIGH-COST INNOVATIVE THERAPIES: GLOBAL LESSONS FROM EUROPE AND THE US
Authors: Carr D, Ermacora P, Nicholson T, Grosvenor A
PHP206: TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?
Authors: Khogeer B, Anjarwalla N, Doolub N, Grosvenor A
PRM209: HOW DO WE MEASURE UTILITIES OUTSIDE OF TRIALS IN RARE DISEASES?
Authors: Lloyd A, Dean R, Jensen I, Maru B, Dabbous O
PCN53: STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS
Authors: Lorenzi M, Amonkar M, Zhang J, Mehta S, Liaw K
PCN34: PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC – A NETWORK META-ANALYSIS
Authors: Frederickson A, Arndorfer S, Lorenzi M, Insinga R, Chandwani S, Burke T
PRM25: INCORPORATING EXPERT OPINION TO IMPROVE ESTIMATES OF LONG-TERM SURVIVAL WHEN FOLLOW-UP OF EMPIRICAL STUDIES IS SHORT
Authors: Ayers D, Cope S, Jansen JP.
PRM94: ALIGNING TEXT MINING AND MACHINE LEARNING ALGORITHMS WITH BEST PRACTICES FOR STUDY SELECTION IN SYSTEMATIC LITERATURE REVIEWS
Authors: Popoff E, Jansen JP, Besada M, Cope S Kanters S.
PND11: INDIRECT TREATMENT COMPARISON OF AVXS-101 TO NUSINERSEN FOR THE TREATMENT OF TYPE 1 SPINAL MUSCULAR ATROPHY
Authors: Lorenzi M, Dabbous O, Jansen JP, Maru B, Sproule DM, Feltner D, White C.
PCN21: COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON
Authors: Cope S, Popoff E, Keeping S, Goldgrub R, Jansen JP, Penrod JR, Abraham P, Camidge DR, Korytowsky B, Gu T, Schoenherr N, Juarez-Garcia A, Le T, Yuan Y.
PHP285: EXPERTS IN HEALTH TECHNOLOGY ASSESSMENT ARE CONCERNED ABOUT THE TRANSLATION FROM EVIDENCE TO DECISION-MAKING
Authors: Shih T, Toor K, Yoon L, Barron R, Cope S, Huber C, Arellano J, Jansen JP.
PRM13: OPEN-SOURCE SOFTWARE FOR DEVELOPING COMPUTATIONALLY EFFICIENT COST-EFFECTIVENESS MODELS TO EVALUATE SEQUENTIAL TREATMENT STRATEGIES IN ONCOLOGY
Authors: Incerti D, Jansen JP.
PCN169: A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCER
Authors: Jansen JP, Incerti D, Shafrin J, Fredericksen A, Lakdawalla DM, Reckamp K.
PCN167: IMPROVEMENT OF AN OPEN-SOURCE COSTEFFECTIVENESS MODEL BASED ON PUBLIC FEEDBACK
Authors: Incerti D, Shafrin J, Lakdawalla D, Zhao LM, Linthicum M, Jansen JP.
PMS113: TOWARD PATIENT-CENTERED VALUE ASSESSMENT: LESSONS FROM THE IVI OPEN-SOURCE VALUE PROJECT
Authors: May SG, Shafrin J, Linthicum M, Incerti D, Jansen JP, Lakdawalla DN, Bright J.
Issue Panels
IP6: DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?
Moderator: Precision Xtract's Ross MacLean, MD; Panelists: Lou Garrison, Representing ISPOR Special Task Force; Mark Sculpher, European HTA perspective; Jens Grueger VP, Head of Global Pricing & Market Access, Roche Pharmaceuticals.
IP22: ARE SINGLE-ARM CLINICAL TRIALS SUFFICIENT TO ASSESS VALUE IN ONCOLOGY AND RARE DISEASES?
Panelists: Jansen JP, Dabbous O, Toumi M
Workshop
W19: YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES
Presenters: Thom H, Incerti D, Jansen JP, Baio G.
(Bold denotes Precision author)
Contact us
Discover exactly what Precision can do for you. We look forward to learning about your needs, exploring how we can support you, and sharing our proven approaches. For information and inquiries, please contact:
Zac Stillerman
Zac Stillerman
President and General Manager
phone-icon +1 240.316.3451
Larry Blandford
Larry Blandford, PharmD
Executive Vice President and Managing Partner
phone-icon +1 212.686.2650
J. Bruce Leavitt
J. Bruce Leavitt, MBA
Executive Vice President and Managing Partner
phone-icon +1 203.487.5240
Ross Maclean
Ross Maclean, MD, PHD, MBA
Senior Vice President and Head of Medical Affairs
phone-icon +1 310.984.7708
Harry Grant Schiavi
Harry Grant Schiavi
Managing Partner, Insight Strategy Advisors
phone-icon +1 302.379.1702
arrow-top